Watching NRX Pharmaceuticals; Traders Circulate MDPI Link Titled 'NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In VITR'
Portfolio Pulse from Benzinga Newsdesk
Traders are closely monitoring NRX Pharmaceuticals following the circulation of an MDPI article link, which reports that NRX-101, a combination of D-Cycloserine and Lurasidone, is effective against drug-resistant urinary pathogens in vitro.
March 28, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NRX Pharmaceuticals is in the spotlight due to a study showing NRX-101's effectiveness against drug-resistant urinary pathogens.
The circulation of positive study results about NRX-101's effectiveness could lead to increased investor interest and optimism about NRX Pharmaceuticals' future prospects, potentially driving up the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90